NeurAxis Inc., a medical technology company focused on neuromodulation therapies for chronic conditions, has successfully closed a registered direct offering, raising approximately $5.0 million. The company issued 1,538,461 shares of common stock at $3.25 per share. This infusion of capital, alongside over $1 million from recent warrant exercises, aims to bolster NeurAxis's financial position and support the growth of its IB-Stim therapy, which recently received FDA clearance for expanded pediatric use. Craig-Hallum Capital Group served as the exclusive placement agent for the offering.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.